cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihaemorrhagiás - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
diovan 320 mg filmtabletta
novartis hungária kft. pharma részlege - a valzartán -
valsartan-ratiopharm 40 mg filmtabletta
ratiopharm gmbh - a valzartán -
valsartan-ratiopharm 80 mg filmtabletta
ratiopharm gmbh - a valzartán -
valsartan-ratiopharm 160 mg filmtabletta
ratiopharm gmbh - a valzartán -
valsol 80 mg filmtabletta
laboratorios liconsa sa - a valzartán -
valsol 160 mg filmtabletta
laboratorios liconsa sa - a valzartán -
valsartan richter 40 mg filmtabletta
richter gedeon nyrt. - a valzartán -
valsartan richter 80 mg filmtabletta
richter gedeon nyrt. - a valzartán -
valsartan richter 160 mg filmtabletta
richter gedeon nyrt. - a valzartán -